Brind.

Corporate news includes the acquisition of Vidya Therapeutics by Processa Pharmaceuticals, the $7.2 billion acquisition of Receptos by Celgene, and updates regarding Gujrathi's professional history with BMS.

1 report, 1 independent Updated Aug 27

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Sheila Gujrathi Bristol-Myers Squibb Celgene

Keep exploring

The entities involved

Sheila Gujrathi
researcher

Nothing else this week.
Bristol-Myers Squibb
American pharmaceutical company
- Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
- FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09
Celgene
American biopharmaceutical company

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 27sdbj.com